Alkem Laboratories shares slid 3.76% on August 14, 2026, following a 21.7% decline in quarterly net profit. Investors reacted to rising expenses that squeezed margins and the recent 'Official Action Indicated' classification by the US FDA for the company's Daman facility.
Alkem Laboratories shares faced selling pressure on Friday, August 14, 2026, dropping 3.76% to trade at Rs 5,215. This decline followed the company's announcement of its financial performance for the first quarter of the 2027 fiscal year, which showed a disconnect between revenue growth and bottom-line profitability.
Profitability and Margin Pressure
For the quarter ending June 30, 2026, the company reported a consolidated revenue from operations of Rs 3,740 crore, reflecting a 10.9% increase compared to the same period last year. However, net profit fell by 21.7% year-on-year to Rs 520 crore. This profit contraction highlights a struggle to maintain efficiency, as EBITDA margins narrowed by 140 basis points to 20.5% during the quarter. The drop in margins suggests that operating expenses, including raw material and other costs, have been rising faster than the company's ability to generate profit from its sales.
Regulatory Developments at Daman Facility
Adding to the market caution is the regulatory status of the company’s key manufacturing plant. On August 6, 2026, the US Food and Drug Administration (US FDA) classified Alkem’s Amaliya facility in Daman as 'Official Action Indicated' (OAI). This classification follows an inspection conducted between April 20 and May 1, 2026, which resulted in seven observations. While the company continues to manufacture and supply products to the US market from this site, the OAI status often signals that the regulator has identified issues that need to be addressed before future product approvals from that facility are cleared.
Capacity Expansion and Monitorables
Despite the immediate regulatory and margin challenges, the company is moving ahead with its long-term growth plans. Alkem has approved an investment of up to Rs 75 crore to expand capacity at its Baddi facility in Himachal Pradesh. For shareholders, the key monitorables will be how quickly the company can stabilize its profit margins and resolve the regulatory observations at the Daman site. Investors are likely to track management’s commentary on cost control measures and the timeline for clearing the US FDA concerns, as these will directly influence the company’s ability to sustain growth in its US and domestic operations.